Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review

Abstract

Chronic kidney disease (CKD) and nonalcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) account for substantial financial burden worldwide. These alarming features call for enhanced efforts to prevent and manage the development and progression of CKD. Accumulating evidence supporting a causal role of NAFLD/MAFLD/MASLD-in CKD opens new horizons to achieve this aim. Recent epidemiological studies and meta-analyses exploring the association of NAFLD/MAFLD/MASLD with CKD and the characteristics of NAFLD/MAFLD/MASLD associated with the odds of incident CKD are discussed. The involved pathomechanisms, including the common soil hypothesis, genetics, gut dysbiosis, and portal hypertension, are examined in detail. Finally, lifestyle changes (diet and physical exercise), direct manipulation of gut microbiota, and drug approaches involving statins, renin-angiotensin-aldosterone system inhibitors, GLP-1 Receptor Agonists, Sodium-glucose cotransporter-2, pemafibrate, and vonafexor are examined within the context of prevention and management of CKD among those with NAFLD/MAFLD/MASLD. The evolving NAFLD/MAFLD/MASLD nomenclature may generate confusion among practicing clinicians and investigators. However, comparative studies investigating the pros and contra of different nomenclatures may identify the most useful definitions among NAFLD/MAFLD/MASLD and strategies to identify, prevent, and halt the onset and progression of CKD.

Keywords

Cardiovascular risk / epidemiology / FXR-agonists / gliflozins / gut dysbiosis / molecular pathogenesis / pemafibrate / renin-angiotensin-aldosterone system inhibitors / statins

References

[1] Lonardo A,Alswat KA.History of nonalcoholic fatty liver disease.Int J Mol Sci2020;21:5888 PMCID:PMC7460697

[2] Loria P,Carulli N.Should nonalcoholic fatty liver disease be renamed?.Dig Dis2005;23:72-82

[3] Méndez-Sánchez N,Gish RG.Global multi-stakeholder consensus on the redefinition of fatty liver diseaseGlobal multi-stakeholder endorsement of the MAFLD definition.Lancet Gastroenterol Hepatol2022;7:388-90.

[4] Rinella ME,Ratziu V.NAFLD Nomenclature consensus groupA multisociety Delphi consensus statement on new fatty liver disease nomenclature.J Hepatol2023;79:1542-56

[5] Bilson J,Byrne CD.Steatotic liver disease, MASLD and risk of chronic kidney disease.Diabetes Metab2024;50:101506

[6] Byrne CD.MASLD, MAFLD, or NAFLD criteria: have we re-created the confusion and acrimony surrounding metabolic syndrome?.Metab Target Organ Damage2024;4:10.

[7] Duseja A,De A.Indian national association for study of the liver (INASL) guidance paper on nomenclature, diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD).J Clin Exp Hepatol2023;13:273-302 PMCID:PMC10025685

[8] Kaya E.Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease.Ther Adv Endocrinol Metab2022;13:20420188221139650 PMCID:PMC9747887

[9] Huang XJ,Zhou BQ,Xia YQ.Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors.World J Hepatol2023;15:985-1000 PMCID:PMC10494565

[10] Hagström H,Ekstedt M.99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical.J Hepatol2024;80:e76-7

[11] Vaidya SR. Chronic renal failure. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535404/ [Last accessed on 1 Apr 2024]

[12] Ryu H,Kang E.KNOW-CKD Study GroupComparison of outcomes of chronic kidney disease based on etiology: a prospective cohort study from KNOW-CKD.Sci Rep2023;13:3570 PMCID:PMC9981888

[13] Chen J,Hamm LL.The metabolic syndrome and chronic kidney disease in U.S. adults.Ann Intern Med2004;140:167-74

[14] Ndumele CE,Chow SL.American Heart AssociationCardiovascular-kidney-metabolic health: a presidential advisory from the american heart association.Circulation2023;148:1606-35

[15] Matsushita K,Wang AY,Schaeffner E.Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease.Nat Rev Nephrol2022;18:696-707

[16] Zoccali C,Adamczak M.Cardiovascular complications in chronic kidney disease: a review from the European renal and cardiovascular medicine working group of the European renal association.Cardiovasc Res2023;119:2017-32 PMCID:PMC10478756

[17] Luo M,Luo S.Causal effects of gut microbiota on the risk of chronic kidney disease: a Mendelian randomization study.Front Cell Infect Microbiol2023;13:1142140 PMCID:PMC10102584

[18] Riazi K,Charette JH.The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2022;7:851-61

[19] Quek J,Wong ZY.Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2023;8:20-30

[20] En Li Cho E,Quek J.Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis.Gut2023;72:2138-48

[21] Ye Q,Yeo YH.Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2020;5:739-52

[22] Liu J,Fu X.Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis.Chin Med J2022;135:1682-91 PMCID:PMC9509027

[23] Xiao J,Chan KE.Hepatic, extra-hepatic outcomes and causes of mortality in NAFLD - an umbrella overview of systematic review of meta-analysis.J Clin Exp Hepatol2023;13:656-65 PMCID:PMC10333954

[24] Stepanova M,Afendy M.Direct and indirect economic burden of chronic liver disease in the United States.Clin Gastroenterol Hepatol2017;15:759-66.e5

[25] Sayiner M,Golabi P,Farhat F.Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population.Hepatol Int2020;14:556-66

[26] Perazzo H,Griep RH.CollaboratorsChanging from NAFLD through MAFLD to MASLD: similar prevalence and risk factors in a large Brazilian cohort.J Hepatol2024;80:e72-4

[27] Kovesdy CP.Epidemiology of chronic kidney disease: an update 2022.Kidney Int Suppl2022;12:7-11 PMCID:PMC9073222

[28] Arabi T,Sabbah BN.Obesity-related kidney disease: Beyond hypertension and insulin-resistance.Front Endocrinol2022;13:1095211 PMCID:PMC9884830

[29] Zheng J,Rasheed H.Trans-ethnic Mendelian-randomization study reveals causal relationships between cardiometabolic factors and chronic kidney disease.Int J Epidemiol2022;50:1995-2010 PMCID:PMC8743120

[30] Tsao HM,Chang YC.Serum urate and risk of chronic kidney disease: a mendelian randomization study using Taiwan biobank.Mayo Clin Proc2023;98:513-21

[31] Deprince A,Staels B.Dysregulated lipid metabolism links NAFLD to cardiovascular disease.Mol Metab2020;42:101092 PMCID:PMC7600388

[32] Kim S,Sung E.Non-alcoholic fatty liver disease and the development of nephrolithiasis: A cohort study.PLoS One2017;12:e0184506 PMCID:PMC5657618

[33] Liu Z,Huang H,Xu C.Association between serum uric acid levels and long-term mortality of metabolic dysfunction-associated fatty liver disease: a nationwide cohort study.Diabetol Metab Syndr2023;15:27 PMCID:PMC9948545

[34] Chen TK,Grams ME.Chronic kidney disease diagnosis and management: a review.JAMA2019;322:1294-304 PMCID:PMC7015670

[35] Kalantar-Zadeh K,Nitsch D,Perkovic V.Chronic kidney disease.Lancet2021;398:786-802

[36] Sanchez-Niño MD,Ramos AM,Ortiz A.Translational science in chronic kidney disease.Clin Sci2017;131:1617-29

[37] Gandjour A,Wehmeyer W,Tschulena U.Costs of patients with chronic kidney disease in Germany.PLoS One2020;15:e0231375 PMCID:PMC7182232

[38] Wang TY,Bu ZY.Association of metabolic dysfunction-associated fatty liver disease with kidney disease.Nat Rev Nephrol2022;18:259-68.

[39] Mantovani A,Cattazzo F,Cappelli D.MAFLD and CKD: an updated narrative review.Int J Mol Sci2022;23:7007 PMCID:PMC9266672

[40] Theofilis P,Kalaitzidis RG.Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations.World J Gastroenterol2022;28:5691-706 PMCID:PMC9627426

[41] Sun DQ,Byrne CD.An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease.Hepatobiliary Surg Nutr2023;12:386-403 PMCID:PMC10282675

[42] Nysather J,Manka P,Syn WK.Nonalcoholic fatty liver disease and chronic kidney disease cross talk.Adv Kidney Dis Health2023;30:315-35

[43] Lonardo A,Targher G.Nonalcoholic fatty liver disease and chronic kidney disease: epidemiology, pathogenesis, and clinical and research implications.Int J Mol Sci2022;23:13320 PMCID:PMC9654863

[44] Musso G,Tabibian JH.Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.PLoS Med2014;11:e1001680 PMCID:PMC4106719

[45] Liu HW,Kuo KL.Association of nonalcoholic fatty liver and chronic kidney disease: An analysis of 37,825 cases from health checkup center in Taiwan.Ci Ji Yi Xue Za Zhi2020;32:65-9 PMCID:PMC7015019

[46] Akahane T,Namisaki T.Association between non-alcoholic fatty liver disease and chronic kidney disease: a cross-sectional study.J Clin Med2020;9:1635 PMCID:PMC7356359

[47] Deng Y,Gong R.Association between metabolic associated fatty liver disease and chronic kidney disease: a cross-sectional study from NHANES 2017-2018.Diabetes Metab Syndr Obes2021;14:1751-61 PMCID:PMC8075735

[48] Sun DQ,Wang TY.MAFLD and risk of CKD.Metabolism2021;115:154433

[49] Su W,Xiao L.Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease.Front Public Health2022;10:1047794 PMCID:PMC9676964

[50] Agustanti N,Damara FA.The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: a systematic review and meta-analysis.Diabetes Metab Syndr2023;17:102780

[51] Mantovani A,Beatrice G.Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.Gut2022;71:156-62

[52] Mantovani A,Beatrice G.Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.Gut2022;71:156-62

[53] Yi M,Feng X.Extrahepatic morbidities and mortality of NAFLD: an umbrella review of meta-analyses.Aliment Pharmacol Ther2022;56:1119-30

[54] Tanaka M,Takahashi S.Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.Nephrol Dial Transplant2023;38:700-11

[55] Jung CY,Park KH.Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study.Diabetes Metab2022;48:101344

[56] Hashimoto Y,Okamura T.Metabolic associated fatty liver disease is a risk factor for chronic kidney disease.J Diabetes Investig2022;13:308-16 PMCID:PMC8847128

[57] Zhang Y,Liu Y.Adherence to healthy lifestyle was associated with an attenuation of the risk of chronic kidney disease from metabolic dysfunction-associated fatty liver disease: results from two prospective cohorts.Diabetes Metab Syndr2023;17:102873

[58] Pan LL,Huang ZF.Intrahepatic triglyceride content is independently associated with chronic kidney disease in obese adults: a cross-sectional study.Metabolism2015;64:1077-85

[59] Zuo G,Xin Z.New nonalcoholic fatty liver disease and fibrosis progression associate with the risk of incident chronic kidney disease.J Clin Endocrinol Metab2021;106:e3957-68

[60] Ciardullo S,Trevisan R.Liver stiffness, albuminuria and chronic kidney disease in patients with NAFLD: a systematic review and meta-analysis.Biomolecules2022;12:105 PMCID:PMC8773568

[61] Seo DH,Cho Y.Advanced liver fibrosis is associated with chronic kidney disease in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease.Diabetes Metab J2022;46:630-9 PMCID:PMC9353562

[62] Sun Y,Huang Z.Fibrosis risk in nonalcoholic fatty liver disease is related to chronic kidney disease in older type 2 diabetes patients.J Clin Endocrinol Metab2022;107:e3661-9

[63] Chung GE,Lee KN.Association between fatty liver index and risk of end-stage renal disease stratified by kidney function in patients with type 2 diabetes: a nationwide population-based study.Diabetes Metab2023;49:101454

[64] Lonardo A.The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management: a narrative review focusing on principal risk modifiers.Expert Rev Clin Pharmacol2023;16:891-911

[65] Machado MV,Xie G.Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease.PLoS One2015;10:e0127991 PMCID:PMC4446215

[66] Suzuki A.Nonalcoholic steatohepatitis.Annu Rev Med2017;68:85-98

[67] Wentworth BJ.Pearls and pitfalls in nonalcoholic fatty liver disease: tricky results are common.Metab Target Organ Damage2021;1:2 PMCID:PMC9455931

[68] Arrese M,Barrera F,Valenti L.Insights into nonalcoholic fatty-liver disease heterogeneity.Semin Liver Dis2021;41:421-34 PMCID:PMC8492194

[69] Pal P,Ray S.Heterogeneity of non-alcoholic fatty liver disease: implications for clinical practice and research activity.World J Hepatol2021;13:1584-610 PMCID:PMC8637673

[70] Lonardo A,Osna N.Effect of cofactors on NAFLD/NASH and MAFLD - a paradigm illustrating the pathomechanics of organ dysfunction.Metab Target Organ Damage2022;2:12 PMCID:DOI:

[71] Baratta F,Bini S.Heterogeneity of non-alcoholic fatty liver disease (NAFLD): implication for cardiovascular risk stratification.Atherosclerosis2022;357:51-9

[72] Pirola CJ.Advances in our understanding of the molecular heterogeneity of fatty liver disease: toward informed treatment decision making.Expert Rev Gastroenterol Hepatol2023;17:317-24

[73] Trépo E.Update on NAFLD genetics: From new variants to the clinic.J Hepatol2020;72:1196-209

[74] Lonardo A.Principles of risk stratification in nonalcoholic fatty liver disease. A narrative review emphasizing non-invasive strategies.Explor Dig Dis2:188-201.

[75] Sun DQ,Xu G.PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels.Liver Int2020;40:107-19

[76] Mantovani A,Zusi C.PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: clinical and experimental findings.Liver Int2020;40:1130-41

[77] Akuta N,Arase Y.PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD.BMC Gastroenterol2021;21:434 PMCID:PMC8603578

[78] Mantovani A,Margarita S.Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle-aged individuals with metabolic dysfunction.Aliment Pharmacol Ther2023;57:1093-102

[79] Mantovani A.PNPLA3 rs738409 polymorphism and kidney dysfunction: an association beyond nonalcoholic fatty liver disease?.Metab Target Organ Damage2023;3:18

[80] Lonardo A,Targher G."Not all forms of NAFLD were created equal". Do metabolic syndrome-related NAFLD and PNPLA3-related NAFLD exert a variable impact on the risk of early carotid atherosclerosis?.Atherosclerosis2017;257:253-5

[81] Nashar K.Relationship between chronic kidney disease and metabolic syndrome: current perspectives.Diabetes Metab Syndr Obes2014;7:421-35 PMCID:PMC4173754

[82] Selby NM.An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines.Diabetes Obes Metab2020;22 Suppl 1:3-15

[83] Iqbal J,Nawaz MA.Risk of incident chronic kidney disease in metabolically healthy obesity and metabolically unhealthy normal weight: a systematic review and meta-analysis.Obes Rev2024;25:e13656

[84] Ruan X.Metabolic syndrome and chronic kidney disease.J Diabetes2009;1:236-45

[85] Masenga SK,Chakulya M.Mechanisms of oxidative stress in metabolic syndrome.Int J Mol Sci2023;24:7898 PMCID:PMC10178199

[86] Stenvinkel P,Devarajan P.Chronic inflammation in chronic kidney disease progression: role of Nrf2.Kidney Int Rep2021;6:1775-87 PMCID:PMC8258499

[87] Dorotea D,Ha H.Recent insights into SREBP as a direct mediator of kidney fibrosis via lipid-independent pathways.Front Pharmacol2020;11:265 PMCID:PMC7092724

[88] Avraham S,Chung JJ,Shaw AS.The mesangial cell - the glomerular stromal cell.Nat Rev Nephrol2021;17:855-64

[89] Costantino VV,Bocanegra V.Molecular mechanisms of hypertensive nephropathy: renoprotective effect of losartan through Hsp70.Cells2021;10:3146. PMCID:PMC8619557

[90] Eshraghi Y,Gheisari Y.Proteomics to metabolomics: a new insight into the pathogenesis of hypertensive nephropathy.Kidney Blood Press Res2023;48:710-26 PMCID:PMC10681119

[91] Alicic RZ,Tuttle KR.Diabetic kidney disease: challenges, progress, and possibilities.Clin J Am Soc Nephrol2017;12:2032-45 PMCID:PMC5718284

[92] DeFronzo RA,Awad AS.Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.Nat Rev Nephrol2021;17:319-34.

[93] Berfield AK,Abrass CK.IGF-1-induced lipid accumulation impairs mesangial cell migration and contractile function.Kidney Int2002;62:1229-37

[94] Guo Y,Zhang X.Role of FXR in renal physiology and kidney diseases.Int J Mol Sci2023;24:2408 PMCID:PMC9916923

[95] Zhu JB,Li J.Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury.Eur J Pharmacol2018;838:60-8

[96] Palladini G,Di Pasqua LG.Obeticholic acid reduces kidney matrix metalloproteinase activation following partial hepatic ischemia/reperfusion injury in rats.Pharmaceuticals2022;15:524 PMCID:PMC9145209

[97] Gege C,Hambruch N,Kremoser C. Nonsteroidal FXR ligands: current status and clinical applications. In: Fiorucci S, Distrutti E, editors. Bile Acids and Their Receptors. Cham: Springer International Publishing; 2019. pp. 167-205.

[98] Andres-Hernando A,Kuwabara M.Obesity causes renal mitochondrial dysfunction and energy imbalance and accelerates chronic kidney disease in mice.Am J Physiol Renal Physiol2019;317:F941-8

[99] Søgaard SB,Taghavi I.Super-resolution ultrasound imaging provides quantification of the renal cortical and medullary vasculature in obese zucker rats: a pilot study.Diagnostics2022;12:1626 PMCID:PMC9318608

[100] Hashemi L,Arif Y.Serum low-density lipoprotein cholesterol and cardiovascular disease risk across chronic kidney disease stages (data from 1.9 million United States veterans).Am J Cardiol2022;170:47-55

[101] Baragetti A,Sarcina C.High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease.J Intern Med2013;274:252-62

[102] Baragetti A,Strazzella A.Low plasma lecithin: cholesterol acyltransferase (LCAT) concentration predicts chronic kidney disease.J Clin Med2020;9:2289 PMCID:PMC7408930

[103] Guerra S,Gastaldelli A.Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis.Eur J Clin Invest2022;52:e13695

[104] Jia J,Gao M.Assessment of causal direction between gut microbiota-dependent metabolites and cardiometabolic health: a bidirectional mendelian randomization analysis.Diabetes2019;68:1747-55

[105] Mazidi M,Covic A,Banach M.Adverse impact of desulfovibrio spp. and beneficial role of anaerostipes spp. on renal function: insights from a mendelian randomization analysis.Nutrients2020;12:2216 PMCID:PMC7468709

[106] Luo Q,Chen X,Chen J.Effects of gut microbiota and metabolites on heart failure and its risk factors: a two-sample mendelian randomization study.Front Nutr2022;9:899746 PMCID:PMC9253861

[107] Li N,Wei P.Causal effects of specific gut microbiota on chronic kidney diseases and renal function-a two-sample mendelian randomization study.Nutrients2023;15:360 PMCID:PMC9863044

[108] Gagnon E,Manikpurage HD.Impact of the gut microbiota and associated metabolites on cardiometabolic traits, chronic diseases and human longevity: a Mendelian randomization study.J Transl Med2023;21:60 PMCID:PMC9887809

[109] Pantazi AC,Nori W.Clinical perspectives of gut microbiota in patients with chronic kidney disease and end-stage kidney disease: where do we stand?.Biomedicines2023;11:2480 PMCID:PMC10525496

[110] Feng Z,Dong S.Association between gut dysbiosis and chronic kidney disease: a narrative review of the literature.J Int Med Res2021;49:3000605211053276 PMCID:PMC8554569

[111] Di Paola R,Izhar R.Possible effects of uremic toxins p-cresol, indoxyl sulfate, p-cresyl sulfate on the development and progression of colon cancer in patients with chronic renal failure.Genes2023;14:1257 PMCID:PMC10298729

[112] Velasquez MT,Manal A.Trimethylamine N-Oxide: the good, the bad and the unknown.Toxins2016;8:326 PMCID:PMC5127123

[113] Zeng Y,Fang X.Gut microbiota-derived trimethylamine N-oxide and kidney function: a systematic review and meta-analysis.Adv Nutr2021;12:1286-304 PMCID:PMC8321840

[114] Papandreou C,Bellamine A.Trimethylamine N-oxide in relation to cardiometabolic health-cause or effect?.Nutrients2020;12:1330 PMCID:PMC7284902

[115] Tang WH,Kennedy DJ.Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease.Circ Res2015;116:448-55 PMCID:PMC4312512

[116] Tao P,Wang Q,Cao M.The role and mechanism of gut microbiota-derived short-chain fatty in the prevention and treatment of diabetic kidney disease.Front Immunol2022;13:1080456 PMCID:PMC9806165

[117] Portincasa P,Vacca M.Gut microbiota and short chain fatty acids: implications in glucose homeostasis.Int J Mol Sci2022;23:1105 PMCID:PMC8835596

[118] Everard A.Gut microbiota and GLP-1.Rev Endocr Metab Disord2014;15:189-96

[119] Kimura I,Ohue-Kitano R.Free fatty acid receptors in health and disease.Physiol Rev2020;100:171-210

[120] Secor JD,Tsikis ST,Puder M.Free fatty acid receptors as mediators and therapeutic targets in liver disease.Front Physiol2021;12:656441 PMCID:PMC8058363

[121] Hidalgo MA,Burgos RA.Long chain fatty acids as modulators of immune cells function: contribution of FFA1 and FFA4 receptors.Front Physiol2021;12:668330 PMCID:PMC8280355

[122] Kim MH,Park JH,Kim CH.Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice.Gastroenterology2013;145:396-406.e1

[123] Mazidi M,Banach M.Higher plasma levels of valerate produced by gut microbiota may have a beneficial impact on renal function.J Am Nutr Assoc2023;42:534-40

[124] Farrell GC,McCuskey RS.Hepatic microcirculation in fatty liver disease.Anat Rec2008;291:684-92

[125] Francque S,Chatterjee S.Non-alcoholic steatohepatitis induces non-fibrosis-related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model.Liver Int2010;30:365-75

[126] Francque S,Mertens I.Visceral adiposity and insulin resistance are independent predictors of the presence of non-cirrhotic NAFLD-related portal hypertension.Int J Obes2011;35:270-8

[127] Vilar-Gomez E,Friedman SL.Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis.Aliment Pharmacol Ther2017;45:332-44

[128] Bruinius JW,Chen J.CRIC Study InvestigatorsSelf-reported physical activity and cardiovascular events in adults with CKD: findings from the CRIC (chronic renal insufficiency cohort) study.Am J Kidney Dis2022;80:751-61.e1 PMCID:PMC9691530

[129] Hamada S,Yamada K.Steatosis is involved in the progression of kidney disease in a high-fat-diet-induced non-alcoholic steatohepatitis mouse model.PLoS One2022;17:e0265461 PMCID:PMC8926260

[130] Bier A,Khasbab R,Grossman E.High-fructose diet increases renal ChREBPβ expression, leading to intrarenal fat accumulation in a rat model with metabolic syndrome.Biology2022;11:618 PMCID:PMC9027247

[131] Abbate M,Montemayor S.Animal fat intake is associated with albuminuria in patients with non-alcoholic fatty liver disease and metabolic syndrome.Nutrients2021;13:1548 PMCID:PMC8147815

[132] Meléndez-Salcido CG,Pérez-Vázquez V.Hypercaloric diet promotes metabolic disorders and impaired kidney function.Curr Pharm Des2022;28:3127-39

[133] Mann JP.What lipodystrophies teach us about the metabolic syndrome.J Clin Invest2019;129:4009-21 PMCID:PMC6763226

[134] Kalavalapalli S,Lomonaco R.Adipose tissue insulin resistance predicts the severity of liver fibrosis in patients with type 2 diabetes and NAFLD.J Clin Endocrinol Metab2023;108:1192-201

[135] Mocciaro G. Obesity-related insulin resistance: the central role of adipose tissue dysfunction. In: Eckel J, Clément K, editors. From Obesity to Diabetes. Cham: Springer International Publishing; 2022. pp. 145-64.

[136] Koppe L.The impact of dietary nutrient intake on gut microbiota in the progression and complications of chronic kidney disease.Kidney Int2022;102:728-39

[137] Yang M,He L,Zhao L.Intermittent fasting-a healthy dietary pattern for diabetic nephropathy.Nutrients2022;14:3995 PMCID:PMC9571963

[138] Vilar-Gomez E,Calzadilla-Bertot L.Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis.Gastroenterology2015;149:367-78.e5; quiz e14

[139] Ruggenenti P,Ruggiero B.CRE.S.O. Study Group. Renal and systemic effects of calorie restriction in patients with type 2 diabetes with abdominal obesity: a randomized controlled trial.Diabetes2017;66:75-86

[140] Sumida K,Yuzefpolskaya M,Demmer RT.Gut microbiota-targeted interventions in the management of chronic kidney disease.Semin Nephrol2023;43:151408 PMCID:PMC10783887

[141] Coutinho-Wolino KS,Mota JC,Guimarães JT.Blueberry, cranberry, raspberry, and strawberry as modulators of the gut microbiota: target for treatment of gut dysbiosis in chronic kidney disease?.Nutr Rev2024;82:248-61

[142] Juszczak F,Botton O.Delayed exercise training improves obesity-induced chronic kidney disease by activating AMPK pathway in high-fat diet-fed mice.Int J Mol Sci2020;22:350 PMCID:PMC7795787

[143] Jung CY,Lee M.Exercise reduces the risk of chronic kidney disease in individuals with nonalcoholic fatty liver disease: a nationwide cohort study.Diabetes Metab2022;48:101362

[144] Zheng T,Kamili K.The relationship between alcohol consumption and chronic kidney disease in patients with nonalcoholic fatty liver disease.Scand J Gastroenterol2024;Online ahead of print:1-9

[145] Wright WL,Brunton S.Beyond blood glucose and blood pressure control in type 2 diabetes: alternative management strategies to prevent the development and progression of CKD.J Prim Care Community Health2023;14:21501319231153599 PMCID:PMC10031227

[146] Brar S,James MT,Pannu N.Interdisciplinary Chronic Disease Collaboration (ICDC)Processes of care after hospital discharge for survivors of acute kidney injury: a population-based cohort study.Am J Kidney Dis2024;83:216-28

[147] Maxson R,Sewell J.SGLT2 inhibitors to slow chronic kidney disease progression: a review.Clin Ther2024;46:e23-8

[148] Lee KC,Lin HC.Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis.Clin Mol Hepatol2023;29:77-98 PMCID:PMC9845678

[149] Zhou H,Zhao W,Zhao Y.Statins on nonalcoholic fatty liver disease: A systematic review and meta-analysis of 14 RCTs.Medicine2023;102:e33981 PMCID:PMC10313296

[150] Jin Z,Zheng C,Weng H.Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials.J Diabetes Complications2023;37:108558

[151] Athyros VG,Daskalopoulos GN,Mikhailidis DP.Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?.Ann Med2011;43:167-71

[152] Spasovski G,Hristov G,Spahia N.A new hope on the horizon for kidney and cardiovascular protection with SGLT2 inhibitors, GLP-1 receptor agonists, and mineralocorticoid receptor antagonists in type 2 diabetic and chronic kidney disease patients.Metab Syndr Relat Disord2024;Online ahead of print

[153] Sumida Y,Toyoda H.Common drug pipelines for the treatment of diabetic nephropathy and hepatopathy: can we kill two birds with one stone?.Int J Mol Sci2020;21:4939 PMCID:PMC7404115

[154] Tilg H,Targher G.NASH drug treatment development: challenges and lessons.Lancet Gastroenterol Hepatol2023;8:943-54

[155] Schnell O,Bergenstal R.CVOT summit 2022 report: new cardiovascular, kidney, and glycemic outcomes.Cardiovasc Diabetol2023;22:59 PMCID:PMC10019427

[156] Lin DS,Hung CS.The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.Diabetologia2021;64:2676-86

[157] Banerjee M,Maisnam I.GLP-1 receptor agonists, SGLT2 inhibitors and noncardiovascular mortality in type 2 diabetes: Insights from a meta-analysis.Diabetes Metab Syndr2024;18:102943

[158] Brockmeyer M,Vargas KG.Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data.J Nephrol2024;Online ahead of print

[159] DeFronzo RA.Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.Diabetes Obes Metab2022;24:1197-205 PMCID:PMC9323420

[160] Agarwal R,Pitt B.FIDELIO-DKD and FIGARO-DKD investigatorsCardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.Eur Heart J2022;43:474-84 PMCID:PMC8830527

[161] Adamson C.Bringing FIDELITY to the estimate of treatment effects of finerenone in chronic kidney disease due to type 2 diabetes.Eur Heart J2022;43:485-7

[162] Yamashita S,Matsuzawa Y.Clinical applications of a novel selective PPARα modulator, pemafibrate, in dyslipidemia and metabolic diseases.J Atheroscler Thromb2019;26:389-402 PMCID:PMC6514171

[163] Horinouchi Y,Yamada Y.Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease.Life Sci2023;321:121590

[164] Iwasaki M,Umezawa Y.Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study.Medicine2023;102:e32818 PMCID:PMC9936022

[165] Hadjivasilis A,Kousios A.The effect of fibrates on kidney function and chronic kidney disease progression: a systematic review and meta-analysis of randomised studies.J Clin Med2022;11:768 PMCID:PMC8836930

[166] Yokote K,Arai H.Long-term efficacy and safety of pemafibrate, a novel selective peroxisome proliferator-activated receptor-α modulator (SPPARMα), in dyslipidemic patients with renal impairment.Int J Mol Sci2019;20:706 PMCID:PMC6386904

[167] Goto H,Hida N.Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients.Nephrol Dial Transplant2023;Online ahead of print:gfad248

[168] Kim DH,Choi HI.The critical role of FXR is associated with the regulation of autophagy and apoptosis in the progression of AKI to CKD.Cell Death Dis2021;12:320 PMCID:PMC7994637

[169] Neuschwander-Tetri BA,Sanyal AJ.NASH Clinical Research NetworkFarnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.Lancet2015;385:956-65 PMCID:PMC4447192

[170] Ratziu V,Loustaud-Ratti V.Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.J Hepatol2023;78:479-92

[171] Dalbeni A,Zoncapè M.Glomerular hyperfiltration: a marker of fibrosis severity in metabolic associated steatotic liver disease in an adult population.Int J Mol Sci2023;24:15837 PMCID:PMC10649990

[172] Golabi P,Kumar A.Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.Metabolism2023;146:155642

[173] Chung GE,Lee KN.Combined effects of chronic kidney disease and nonalcoholic fatty liver disease on the risk of cardiovascular disease in patients with diabetes.Biomedicines2022;10:1245 PMCID:PMC9219946

[174] Hydes TJ,Buchanan R.The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank.BMC Med2023;21:185 PMCID:PMC10193672

[175] Li Y,Gao J.Association of stroke with metabolic dysfunction-associated fatty liver disease with and without CKD.Am J Kidney Dis2024;83:477-88

[176] Triozzi JL,Gregg LP.Incidence and predictors of non-alcoholic fatty liver disease among patients with chronic kidney disease.Nephrol Dial Transplant2021;36:1546-8 PMCID:PMC8502472

[177] Wong F,O'Leary JG.Impact of chronic kidney disease on outcomes in cirrhosis.Liver Transpl2019;25:870-80

[178] Nascimbeni F,Lugari S.Statins and nonalcoholic fatty liver disease in the era of precision medicine: more friends than foes.Atherosclerosis2019;284:66-74

[179] Ballestri S,Romagnoli D,Lonardo A.The role of nuclear receptors in the pathophysiology, natural course, and drug treatment of NAFLD in humans.Adv Ther2016;33:291-319

[180] Kim HS,Kim EH.Association of myosteatosis with nonalcoholic fatty liver disease, severity, and liver fibrosis using visual muscular quality map in computed tomography.Diabetes Metab J2023;47:104-17 PMCID:PMC10040624

[181] Arrese M,Arab JP.Sarcopenia in the setting of nonalcoholic fatty liver.Metab Target Organ Damage2022;2:2.

[182] Jankowski J,Fliser D,Marx N.Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options.Circulation2021;143:1157-72 PMCID:PMC7969169

[183] Mace ML,Morevati M,Lewin E.New insights to the crosstalk between vascular and bone tissue in chronic kidney disease-mineral and bone disorder.Metabolites2021;11:849 PMCID:PMC8708186

[184] Lonardo A.Renaming NAFLD to MAFLD: Could the LDE system assist in this transition?.J Clin Med2021;10:492 PMCID:PMC7866816

[185] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol2020;73:202-9

[186] Malhi H,Lim JK.Precipitous changes in nomenclature and definitions-NAFLD becomes SLD: implications for and expectations of AASLD journals.Hepatology2023;78:1680-1

[187] Di Sessa A,Umano GR,Marzuillo P.MASLD vs. NAFLD: A better definition for children with obesity at higher risk of kidney damage.J Hepatol2024;80:e87-9

[188] Kobayashi N,Nishimura T.Metabolic dysfunction-associated steatotic liver disease criteria may underestimate the number of lean female nonalcoholic fatty liver disease patients with significant liver fibrosis.Hepatol Res2023;

[189] Lonardo A,Caldwell SH.Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature.J Hepatol2024:S0168-8278(24)00054